We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

795 hedge funds and large institutions have $26B invested in Teva Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 69 funds opening new positions, 268 increasing their positions, 324 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less call options, than puts

Call options by funds: $595M | Put options by funds: $620M

8% less first-time investments, than exits

New positions opened: 69 | Existing positions closed: 75

2% less funds holding

Funds holding: 812 → 795 (-17)

2.34% less ownership

Funds ownership: 58.38% → 56.04% (-2.3%)

13% less capital invested

Capital invested by funds: $30B → $26B (-$3.92B)

15% less funds holding in top 10

Funds holding in top 10: 41 → 35 (-6)

17% less repeat investments, than reductions

Existing positions increased: 268 | Existing positions reduced: 324

Holders
795
Holders Change
-17
Holders Change %
-2.09%
% of All Funds
21.21%
Holding in Top 10
35
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-14.63%
% of All Funds
0.93%
New
69
Increased
268
Reduced
324
Closed
75
Calls
$595M
Puts
$620M
Net Calls
-$24.3M
Net Calls Change
-$252M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$310M
2
Franklin Resources
Franklin Resources
California
+$295M
3
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss
Texas
+$202M
4
Capital Research Global Investors
Capital Research Global Investors
California
+$188M
5
JP Morgan Chase
JP Morgan Chase
New York
+$179M

Top Sellers

1
Viking Global Investors
Viking Global Investors
Connecticut
-$420M
2
PC
PointState Capital
New York
-$309M
3
HCM
Highfields Capital Management
Massachusetts
-$280M
4
IC
Institutional Capital
Illinois
-$217M
5
MIFH
Migdal Insurance & Financial Holdings
Israel
-$193M
Name Holding Trade Value Shares
Change 		Change in
Stake
MSU
376
Mizuho Securities USA
New York
$1.5M +$1.7M +32,500 New
UCFA
377
United Capital Financial Advisors
Texas
$1.49M -$216K -4,142 -11%
NCM
378
Northroad Capital Management
New York
$1.48M -$1.99M -38,102 -54%
SLI
379
Sumitomo Life Insurance
Japan
$1.47M -$206K -3,955 -11%
CA
380
Continental Advisors
Utah
$1.47M – – –
DVM
381
Dreman Value Management
Florida
$1.47M -$68.1K -1,305 -4%
PCM
382
Parsons Capital Management
Rhode Island
$1.47M -$33.3K -638 -2%
HDIM
383
Hanson & Doremus Investment Management
Vermont
$1.46M +$230K +4,412 +16%
FO
384
FT Options
Illinois
$1.44M +$1.63M +31,300 New
OCM
385
One Capital Management
California
$1.42M +$78.8K +1,511 +5%
WC
386
Whitnell & Co
Illinois
$1.42M -$63.9K -1,224 -4%
Bessemer Group
387
Bessemer Group
New Jersey
$1.41M -$973K -18,650 -38%
PVWM
388
Point View Wealth Management
New Jersey
$1.41M -$13.5K -258 -0.8%
DM
389
Deerfield Management
New York
$1.38M +$1.57M +30,000 New
TW
390
Transform Wealth
Colorado
$1.37M -$137K -2,620 -8%
COI
391
Connable Office Inc
Michigan
$1.36M +$1.16M +22,230 +300%
FSA
392
Franklin Street Advisors
North Carolina
$1.33M -$22.5K -432 -1%
N
393
Natixis
France
$1.32M +$1.01M +19,393 +206%
FNBOMD
394
First National Bank of Mount Dora
Florida
$1.32M -$937K -17,964 -39%
CCM
395
Catawba Capital Management
Virginia
$1.32M – – –
AIM
396
Anchor Investment Management
South Carolina
$1.32M -$86.3K -1,655 -5%
MCM
397
McKinley Capital Management
Alaska
$1.31M -$43.5M -834,263 -97%
CAM
398
Capstone Asset Management
Texas
$1.31M -$5.22K -100 -0.3%
CT
399
Coastline Trust
Rhode Island
$1.31M – – –
BCFS
400
Butensky & Cohen Financial Security
Florida
$1.31M +$135K +2,580 +10%
14 15
16
17 18

TEVA Hedge Fund Activity: Q3 2016 in Review

795 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2016, worth a combined $26B — down 13% from $30B a quarter earlier.

Sellers outnumbered buyers: 75 funds closed out of TEVA and 69 opened new positions — a net loss of 6 holders — while 324 trimmed existing stakes and 268 added.

The largest buyer was Morgan Stanley, adding an estimated $310M. The largest seller was Viking Global Investors, cutting an estimated $420M.

  • 795 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2016, down from 812 in Q2 2016.
  • Funds reported $26B of Teva Pharmaceuticals stock for Q3 2016, down 13% quarter-over-quarter.
  • 69 funds opened new Teva Pharmaceuticals positions in Q3 2016 and 75 closed out, a net change of -6 holders.
  • The largest Teva Pharmaceuticals buyer in Q3 2016 was Morgan Stanley, an estimated $310M added.
  • The largest Teva Pharmaceuticals seller in Q3 2016 was Viking Global Investors, an estimated $420M sold.

Based on aggregated 13F filings for Q3 2016.